David Johnson, MD
Ophthalmology · Denver, CONPI 1598717977
Payments from drug & device makers
What this record shows
This record is dominated by ownership interests: $5,143 of the $6,622 with a category attached, or 77.7%. US Retina LLC accounts for 77.7% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2021 at $2,180 and has fallen 97.4% since, to $57 in 2024.
Across 32 payments — averaging $206.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- US Retina LLC$5K
- AbbVie$888
- Genentech, Inc.$139
- Genentech USA, Inc.$103
- Novartis$97
- Bausch & Lomb, A Division Of Bausch Health US, LLC$75
- plus $177 from 4 others
What the payments were for
- Grants$831%
- Food & beverage$64610%
- Education$75011%
- Ownership interest$5,14378%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| US Retina LLC | 4 | $5,143 |
| AbbVie(2 entities) | 6 | $888 |
| Genentech, Inc. | 1 | $139 |
| Genentech USA, Inc. | 6 | $103 |
| Novartis | 6 | $97 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $75 |
| Coherus Oncology, Inc. | 2 | $62 |
| Regeneron Healthcare Solutions, Inc. | 3 | $54 |
| Biogen | 2 | $40 |
| Astellas Pharma US Inc | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SUSVIMO$139
How this compares
$6,622 in reported general payments places this provider in the 85th percentile of 262 ophthalmology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Travoprost | 18 | $4,117 |
| Difluprednate | 17 | $2,440 |
| Prednisolone Acetate | 48 | $1,541 |
| Ketorolac Tromethamine | 19 | $495 |
| Timolol Maleate | 36 | $282 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 13 | $191 |
| Latanoprost | 24 | $127 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Denver
- Mark DaceyDenver$370K
- Cristos IfantidesDenver$343K
- Jack ZamoraDenver$172K
- Eva KimDenver$95K
- Michael JansenDenver$95K
- Kingsley OkaforDenver$62K
- Curtis HagedornDenver$25K
- Michael SolomonDenver$12K
- Peter HovlandDenver$10K
- Matthew KrugerDenver$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.